# A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

> **NCT01248364** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 91 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773

## Key facts

- **NCT ID:** NCT01248364
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2014-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248364, "A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01248364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*